Pfizer Czech Republic made a net profit of CZK 134 mil in 2014, down 7.25% when compared to the last year. Total sales reached CZK 4,947 mil, which is down 8.51% when compared to the previous year.
Historically, the company’s net profit reached an all time high of CZK 272 mil in 2008 and an all time low of CZK -29.9 mil in 2005.
In terms of sales, Pfizer Czech Republic reached an all time high of CZK 6,807 mil in 2011 and an all time low of CZK 2,057 mil in 2003.
Pfizer Czech Republic's net profit has grown -2.61% a year on average in the last five years while sales have increased by -1.07% a year since 2009.
The firm generated its shareholders an average return on invested capital of 11.7% in the last five years.
As far as Pfizer Czech Republic's peers are concerned, Roche Czech Republic posted a net profit and sales of CZK 94.9 mil and CZK 4,364 mil in 2014, Bayer Czech Republic generated a net profit of CZK 107 mil (with sales of CZK 4,054 mil) and Amgen Czech Republic netted CZK 40.5 mil (sales of CZK 637 mil).